

MAXIVAC PENTA LIOFILIZADO Y SUSPENSIÓN PARA PREPARACIÓN DE SUSPENSIÓN INYECTABLE PARA PERROS

Authorised

- Leptospira interrogans, serovar Canicola, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain Lederle, Live
- Canine parvovirus, strain Cornell 780916, Live

Product identification

Medicine name:

MAXIVAC PENTA LIOFILIZADO Y SUSPENSIÓN PARA PREPARACIÓN DE SUSPENSIÓN INYECTABLE PARA PERROS

Active substance:

Leptospira interrogans, serovar Canicola, Inactivated
Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
Canine adenovirus 2, strain Manhattan, Live
Canine distemper virus, strain Lederle, Live
Canine parvovirus, strain Cornell 780916, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serovar Canicola, Inactivated

9.00 Organisms / 1.00 millilitre(s)

Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated

9.00 Organisms / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan, Live

4.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine distemper virus, strain Lederle, Live

4.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain Cornell 780916, Live

6.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI03

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Spain

Package description:

Available only in [Spanish](#)

Available only in [Spanish](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Hipra S.A.

Marketing authorisation date:

8/10/2001

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

Spanish Agency For Medicines And Medical Devices

Authorisation number:

1405 ESP

Date of authorisation status change:

8/10/2001

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.